THERAPEUTICS

Trained Therapeutix Discovery appoints Nobel Laureate Dr. James Allison, Dr. Padmanee Sharma, and Dr. Mihai Netea to its Scientific Advisory Board

19th April, 2021
Trained Therapeutix Discovery (“TTxD”) announces that it has extended its Scientific Advisory Board to include James P. Allison, Ph.D. and Padmanee Sharma, M.D., Ph.D. Dr. Allison received the 2018 Nobel Prize in Physiology or Medicine for his work on discovering immune checkpoint blockade and is the Regental Professor and Chair of the Department of Immunology, the Olga Keith Wiess Distinguished University Chair for Cancer Research, Director of the Parker Institute for Cancer Research, and the Executive Director of the Immunotherapy Platform at MD Anderson Cancer Center. Dr. Sharma is a pioneer and world-renowned expert in designing and running immuno-oncology clinical trials and is a practicing immunologist and oncologist at MD Anderson Cancer Center. [...]

Trained Therapeutix Discovery Inc. Appoints Dr. Willem Mulder as Chief Scientific Officer - Expert in Use of Nanomaterials as Immunotherapeutics, Former Professor at Icahn School of Medicine at Mount Sinai, and Professor at Eindhoven University of Technology and Radboud University Medical Center

5 January, 2021
Trained Therapeutix Discovery, Inc. (“TTxD”), an immunotherapy biotech company founded by Jean Boulle Therapeutics, announces the appointment of Prof. Dr. Willem Mulder as Chief Scientific Officer effective 1 January 2021. [...]

Trained Therapeutix Discovery Inc.’s Exclusively Licensed Technology Shown to Suppress Cancer Growth

2 November, 2020
Trained Therapeutix Discovery, Inc. (“TTxD”), an immunotherapy biotech company founded by Jean Boulle Therapeutics, notes the results of a preclinical Study (“the Study”) published in Cell showing how nanobiologic immunotherapy promotes trained immunity and elicits a durable anti-tumor response either as a monotherapy or in combination with other checkpoint inhibitor drugs. [...]

Landmark trial shows trained immunity reduces respiratory infections in the elderly by 80% 

September 1 2020
Trained Therapeutix Discovery, Inc. (“TTxD”), an immunotherapy biotech company founded by Jean Boulle Therapeutics, notes the results of a clinical trial1 (“the Trial”) published in Cell showing that trained immunity through the use of BCG vaccination can reduce respiratory tract infections by 80% amongst elderly people including, potentially, COVID-19. [...]

Jean Boulle Medtech’s New Therapeutics Technology Platform Targets Trained Immunity for COVID-19 Patients and Resultant Acute Respiratory Distress Syndrome

April 27 2020
Trained Therapeutix Discovery, Inc. (“TTxD”), an immunotherapy biotech company founded by Jean Boulle Medtech, is testing a unique strategy for treating Acute Respiratory Distress Syndrome1 (“ARDS”), which could prove to be highly effective in saving the lives of COVID–19 patients [...]

HEAD OFFICE
25B Boulevard Royal
L2449 Luxembourg
Grand Duchy Luxembourg

CALL US
Tel: +352 222 512
Fax: +352 222 413

Copyright © 2019 Jean Boulle Group. All rights reserved.